Compare Fiverr International Ltd (FVRR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Fiverr International Ltd trades at $11.48 (market cap $404.45M), while Vertex Pharmaceuticals Incorporated trades at $480.61 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 299.4× Fiverr International Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| FVRR | VRTX | |
|---|---|---|
Market Cap | $404.45M | $121.09B |
Sector | Industrials | Health |
52-Week High | $26.67 | $529.59 |
52-Week Low | $9.62 | $366.54 |
Enterprise Value | $135.05M | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.07, down 1.77% on the day, with a bullish technical signal from moving averages. The company reported revenue of $430.91M in 2025, with net income of $20.98M and improving profit margins. Recent earnings show a mix of beats and one miss, with Q2 2026 results expected soon. Analyst sentiment is mixed, with 41.18% buy ratings and no sell ratings.
The outlook hinges on execution of its strategy shift amid competitive pressures. Risks include declining active buyers and a pending legal investigation. Upside potential exists if spending per buyer growth continues and the company returns to consistent earnings beats, but investor caution is warranted near the 52-week low.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
